Abstract:Background and purpose: Brain cavernous angiomas with symptomatic hemorrhage (CASH) have a high risk of neurological disability from recurrent bleeding. Systematic assessment of baseline features and multisite validation of novel magnetic resonance imaging biomarkers are needed to optimize clinical trial design aimed at novel pharmacotherapies in CASH. Methods: This prospective, multicenter, observational cohort study included adults with unresected, adjudicated brain CASH within the prior year. Six US sites screened and enrolled patients starting August 2018. Baseline demographics, clinical and imaging features, functional status (modified Rankin Scale and National Institutes of Health Stroke Scale), and patient quality of life outcomes (Patient-Reported Outcomes Measurement Information System-29 and EuroQol-5D) were summarized using descriptive statistics. Patient-Reported Outcomes Measurement Information System-29 scores were standardized against a reference population (mean 50, SD 10), and one-sample t test was performed for each domain. A subgroup underwent harmonized magnetic resonance imaging assessment of lesional iron content with quantitative susceptibility mapping and vascular permeability with dynamic contrast-enhanced quantitative perfusion. Results: As of May 2020, 849 patients were screened and 110 CASH cases enrolled (13% prevalence of trial eligible cases). The average age at consent was 46±16 years, 53% were female, 41% were familial, and 43% were brainstem lesions. At enrollment, ≥90% of the cohort had independent functional outcome (modified Rankin Scale score ≤2 and National Institutes of Health Stroke Scale score <5). However, perceived health problems affecting quality of life were reported in >30% of patients (EuroQol-5D). Patients had significantly worse Patient-Reported Outcomes Measurement Information System-29 scores for anxiety (P=0.007), but better depression (P=0.002) and social satisfaction scores (P=0.012) compared with the general reference population. Mean baseline quantitative susceptibility mapping and permeability of CASH lesion were 0.45±0.17 ppm and 0.39±0.31 mL/100 g per minute, respectively, which were similar to historical CASH cases and consistent across sites. Conclusions: These baseline features will aid investigators in patient stratification and determining the most appropriate outcome measures for clinical trials of emerging pharmacotherapies in CASH.

Abstract WP17: Plasma Proteins In Correlation With Lesional Iron Content And Permeability Imaging In Clinical Trial Of Cavernous Angioma With Symptomatic Hemorrhage

Abstract TP12: Changes in Plasma Metabolites Reflect Lesional Iron Content and Permeability Imaging as Monitoring Biomarkers of Hemorrhage in Cavernous Angiomas

Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.

A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)

Abstract P36: Lesional Perfusion and Permeability Are Diagnostic and Prognostic Biomarkers of Cavernous Angioma With Symptomatic Hemorrhage

Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling

Abstract W P43: Extent of “blooming Effect” Predicts Middle Cerebral Artery Recanalization after Intravenous Thrombolysis

Abstract 162: Arterial Aspirate Derived Exosomes From Patients With Large Vessel Occlusion Are Associated With Increased Blood-brain Barrier Permeability, Decreased Endothelial Integrity As Well Poor Clinical And Radiographic Outcomes Following Mechanical Thrombectomy

Cerebral Microbleeds: Burden Assessment by Using Quantitative Susceptibility Mapping

Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth

Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project

Plasma protein alterations during human large vessel stroke: A controlled comparison study

Plasma biomarkers in patients with familial cavernous malformation and their first-degree relatives

Abstract WP275: Longitudinal Biomarker Analysis in Patients With Ischemic Stroke: Exploratory Targeted and Omics Assessments From a Phase 2a Clinical Trial

Serum Markers of Blood-Brain Barrier Remodeling and Fibrosis as Predictors of Etiology and Clinicoradiologic Outcome in Intracerebral Hemorrhage

Abstract TMP1: Multi-omic Biomarker Development In A Mendelian Neurovascular Disease, Cavernous Angioma

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Abstract TMP2: A Framework For The Study Of Hemorrhagic Microangiopathy With Cerebral Cavernous Malformation As A Paradigm

Endothelial receptor proteins in acute venous thrombosis and delayed thrombus resolution in cerebral sinus vein thrombosis

Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in Plasma

Proteomics on human cerebral cavernous malformations reveals novel biomarkers in neurovascular dysfunction for the disease pathology